NL repository
menu
검색
Library
Browse
Communities & Collections
By Date
Authors
Titles
Subject
My Repository
My Account
Receive email updates
Edit Profile
DSpace at EWHA
의료원
의료원
Journal papers
View : 816 Download: 285
Impact of vancomycin MIC on treatment outcomes in invasive Staphylococcus aureus infections
Title
Impact of vancomycin MIC on treatment outcomes in invasive Staphylococcus aureus infections
Authors
Song K.-H.
;
Kim M.
;
Kim C.J.
;
Cho J.E.
;
Choi Y.J.
;
Park J.S.
;
Ahn S.
;
Jang H.-C.
;
Park K.-H.
;
Jung S.-I.
;
Yoon N.
;
Kim D.-M.
;
Hwang J.-H.
;
Lee C.S.
;
Lee J.H.
;
Kwak Y.G.
;
Kim E.S.
;
Park S.Y.
;
Park Y.
;
Lee K.S.
;
Lee Y.-S.
;
Kim H.B.
Ewha Authors
김충종
SCOPUS Author ID
김충종
Issue Date
2017
Journal Title
Antimicrobial Agents and Chemotherapy
ISSN
0066-4804
Citation
Antimicrobial Agents and Chemotherapy vol. 61, no. 3
Keywords
Bacteremia
;
Methicillin resistant
;
Methicillin susceptible
;
MIC
;
Staphylococcus aureus
;
Vancomycin
Publisher
American Society for Microbiology
Indexed
SCIE; SCOPUS
Document Type
Article
Abstract
There are conflicting data on the association of vancomycin MIC (VANMIC) with treatment outcomes in Staphylococcus aureus infections. We investigated the relationship between high VAN-MIC and 30-day mortality and identified the risk factors for mortality in a large cohort of patients with invasive S. aureus (ISA) infections, defined as the isolation of S. aureus from a normally sterile site. Over a 2-year period, 1,027 adult patients with ISA infections were enrolled in 10 hospitals, including 673 (66%) patients with methicillin-resistant S. aureus (MRSA) infections. There were 200 (19.5%) isolates with high VAN-MIC (≥1.5 mg/liter) by Etest and 87 (8.5%) by broth microdilution (BMD). The all-cause 30-day mortality rate was 27.4%. High VAN-MIC by either method was not associated with all-cause 30-day mortality, and this finding was consistent across MIC methodologies and methicillin susceptibilities. We conclude that high VAN-MIC is not associated with increased risk of all-cause 30-day mortality in ISA infections. Our data support the view that VAN-MIC alone is not sufficient evidence to change current clinical practice. Copyright © 2017 American Society for Microbiology. All Rights Reserved.
DOI
10.1128/AAC.01845-16
Appears in Collections:
의료원
>
의료원
>
Journal papers
Files in This Item:
Impact of vancomycin MIC.pdf
(763.22 kB)
Download
Export
RIS (EndNote)
XLS (Excel)
XML
Show full item record
Find@EWHA
트윗하기
BROWSE
Communities & Collections
By Date
Authors
Titles
Subject